Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 5/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554638 | 0.95 | MEN1 (0.55) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL15905303 | 0.92 | PTK2 (0.51) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL1554572 | 0.91 | MEN1 (0.51) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL15918834 | 0.90 | PTK2 (0.52) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL1554621 | 0.87 | MEN1 (0.47) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL1555631 | 0.87 | L3MBTL1 (0.64) | MEN1KMT2ALMNATDP1L3MBTL1 | |
| SCHEMBL2124834 | 0.85 | MEN1 (0.46) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL15647358 | 0.85 | CFTR (0.44) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL2123078 | 0.85 | CFTR (0.45) | PTK2MEN1KMT2ALMNATDP1 | |
| SCHEMBL1555624 | 0.85 | CFTR (0.45) | PTK2MEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655902-B2 | Guanidine derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655902-B2 | Guanidine derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655902-B2 | Guanidine derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2948445-B1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2948445-B1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2948445-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150320757-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| US-20150320757-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| US-20150320757-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| WO-2014116768-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014116768-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320757-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | GMPS, GANC, GUCY1A1 | PTK2 4874/4885MEN1 4734/4885KMT2A 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.